Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

Abstract: The present invention provides capsules having a shell of material that comprises an assembly of a protein, and the capsule is optionally provided with a network of material within the shell that is an assembly of the protein. The assembly of the protein is obtained or obtainable by the aggregation of the protein, optionally together with another protein. The assembly is a non-covalent assembly of a protein.

Abstract: The subject matter disclosed herein relates to methods of identifying pharmacophores and inhibitors against protein aggregation. The present disclosure also provides pharmacophores themselves and medical uses of agents in the treatment of diseases associated with protein aggregation.

Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

Abstract: A thiazolidinedione or rhodanine compound or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, prodrug, derivative, stereoisomer, analog or isotopically labelled derivative thereof, for use in the treatment and/or prevention of an ophthalmological condition, wherein said compound is not Pioglitazone, Rosiglitazone, Rivoglitazone, Balaglitazone or Mitoglitazone.

Abstract: A thiazolidinedione or rhodanine compound or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, prodrug, derivative, stereoisomer, analog or isotopically labelled derivative thereof, for use in the treatment and/or prevention of a protein misfolding disease, wherein said compound is not Pioglitazone, Rosiglitazone, Rivoglitazone, Balaglitazone or Mitoglitazone.

Abstract: Methods for determining the lateral diffusion of one or more components are provided.

Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

Abstract: Methods for determining the lateral diffusion of one or more components are provided.

Abstract: The present invention relates to methods of identifying pharmacophores and inhibitors against protein aggregation. The present invention also provides pharmacophores themselves and medical uses of agents in the treatment of Alzheimer's.

Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

Abstract: A method for determining the diffusion of one or more components, the method includes the steps of (i) providing a component fluid flow having one or more components; (ii) providing a blank fluid flow; (iii) bringing the flow (i) into contact with the flow (ii) in a large cross section channel, thereby to generate two laminar flows; (iv) permitting the laminar flows generated in (iii) to flow from the large cross section channel into a small cross section channel; measuring the lateral diffusion of the one or more components from the component flow into the blank fluid flow in the small cross section channel. Also provided is a diffusion method having the steps of measuring the lateral diffusion of the one or more components from the component flow into the blank fluid flow at a plurality of diffusion times.

Abstract: A method for analyzing a component using a fluidic device. The method includes the steps of providing a distribution of the component across contacting first and second fluid flows; diverting a part of the first fluid flow, a part of the second fluid flow, or parts of the first fluid flow and the second fluid flow, wherein the diverted part includes the component; and analyzing the component in the diverted part of the fluid flow. Optionally the component may be labelled prior to the analyzing step. A flow apparatus for use in the method is also provided.

Abstract: The present invention provides capsules having a shell of material that comprises an assembly of a protein, and the capsule is optionally provided with a network of material within the shell that is an assembly of the protein. The assembly of the protein is obtained or obtainable by the aggregation of the protein, optionally together with another protein. The assembly is a non-covalent assembly of a protein.

Abstract: A method for analyzing a component using a fluidic device. The method includes the steps of providing a distribution of the component across contacting first and second fluid flows; diverting a part of the first fluid flow, a part of the second fluid flow, or parts of the first fluid flow and the second fluid flow, wherein the diverted part includes the component; and analyzing the component in the diverted part of the fluid flow. Optionally the component may be labelled prior to the analyzing step. A flow apparatus for use in the method is also provided.

Abstract: A method for determining the diffusion of one or more components, the method includes the steps of (i) providing a component fluid flow having one or more components; (ii) providing a blank fluid flow; (iii) bringing the flow (i) into contact with the flow (ii) in a large cross section channel, thereby to generate two laminar flows; (iv) permitting the laminar flows generated in (iii) to flow from the large cross section channel into a small cross section channel; measuring the lateral diffusion of the one or more components from the component flow into the blank fluid flow in the small cross section channel. Also provided is a diffusion method having the steps of measuring the lateral diffusion of the one or more components from the component flow into the blank fluid flow at a plurality of diffusion times.

Abstract: A prediction method for predicting the effect of an amino acid modification on the rate of aggregation (solubility) of a reference polypeptide comprising: calculating the difference in hydrophobicity (?Hydr) between the reference polypeptide and a modified polypeptide, calculating the difference in ?-sheet propensity (??Gcoil-?+??G?-coil) between the reference polypeptide and modified polypeptide, calculating the difference in charge (? Charge) between the reference polypeptide and modified polypeptide, and calculating: [x* ?Hydr]+[y*(??Gcoil-?+??G?-coil)]?[z*? Charge], wherein x, y and z are scaling factors.

Abstract: We describe methods for identifying aggregation-prone regions in structured—that is folded—proteins. Embodiments of the method use a local propensity for aggregation (Ai) at an amino acid position, this being determined by a combination of a hydrophobicity value, an ?-helix propensity value, a ?-sheet propensity value, a charge value and a pattern value for the amino acid position. This is combined with local structural stability values for the amino acid positions to identify one or more regions in the amino acid sequence which, in the folded protein, are predicted to promote aggregation.